CA2516291A1 - Dosage form having a saccharide matrix - Google Patents

Dosage form having a saccharide matrix Download PDF

Info

Publication number
CA2516291A1
CA2516291A1 CA002516291A CA2516291A CA2516291A1 CA 2516291 A1 CA2516291 A1 CA 2516291A1 CA 002516291 A CA002516291 A CA 002516291A CA 2516291 A CA2516291 A CA 2516291A CA 2516291 A1 CA2516291 A1 CA 2516291A1
Authority
CA
Canada
Prior art keywords
dosage form
allergen
form according
solid dosage
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002516291A
Other languages
French (fr)
Other versions
CA2516291C (en
Inventor
Christian Gauguin Houghton
Annette Roemmelmayer Lundegaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
Alk-Abello A/S
Christian Gauguin Houghton
Annette Roemmelmayer Lundegaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk-Abello A/S, Christian Gauguin Houghton, Annette Roemmelmayer Lundegaard filed Critical Alk-Abello A/S
Publication of CA2516291A1 publication Critical patent/CA2516291A1/en
Application granted granted Critical
Publication of CA2516291C publication Critical patent/CA2516291C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Abstract

The present invention provides a non-compressed fast-dispersing solid dosage form suitable for oromucosal administration of a pharmaceutically active substance comprising (a) a first matrix forming agent in the form of maltodextrin having a dextrose equivalent (DE) of between 1 and 20,(b) a second matrix forming agent in the form of sorbitol, and (c) the active substance.

Claims (42)

1. A non-compressed fast-dispersing solid dosage form suitable for oromucosal administration of a pharmaceutically active substance comprising (a) a first matrix forming agent in the form of maltodextrin having a dextrose equivalent (DE) of between 1 and 20, (b) a second matrix forming agent in the form of sorbitol, and (c) the active substance.
2. A dosage form according to claim 1 comprising one or more further matrix forming agents.
3. A dosage form according to claim 1 or 2, wherein the further matrix forming agent is a mono-, di- or tri-saccharide.
4. A dosage form according to any of claims 1-3, wherein the further matrix forming agent is mannitol.
5. A dosage form according to any of claims 1-4 further comprising polyethylene glycol (PEG).
6. A dosage form according to any of claims 1-5, wherein maltodextrin is present in an amount of 3-40 % (w/w), preferably 10-35 (w/w) and more preferably 15-25 % (w/w) of the dosing solution.
7. A dosage form according to any of claims 1-6, wherein sorbitol is present in an amount of 0.01-10 %(w/w), preferably 0.05-5 % (w/w) and more preferably 0.1-2 % (w/w) of the dosing solution.
8. A dosage form according to any of claims 4-6, wherein mannitol is present in an amount of 1-20 %(w/w), preferably 2-10 % (w/w) and more preferably 3-6 (w/w) of the dosing solution.
9. A dosage form according to any of claims 5-8, wherein PEG is present in an amount of 1-20 %(w/w), preferably 2-15 % (w/w) and more preferably 3-
10 % (w/w) of the dosing solution.
10. A dosage form according to any of claims 1-9 further comprising one or more additional excipients.
11. A dosage form according to claim 10, wherein the excipient is selected from the group consisting of adjuvants, antacids, diluents, enhancers, mucoadhesive agents, flavouring agents, taste masking agents, preservatives, antioxidants, surfactants, viscosity enhancers, coloring agents, pH modifiers and sweeteners.
12. A dosage form according to any of the preceding claims, wherein the active substance is an allergen.
13. A dosage form according to claim 12, wherein the allergen is selected from the group consisting of tree pollen allergens, grass pollen allergens, mite allergens, insect allergens, venom allergens, animal hair and dandruff allergens and food allergens.
14. A dosage form according to claim 12 or 13, wherein the allergen is in the form of an extract, a purified allergen, a modified allergen or a recombinant allergen or a mutant of a recombinant allergen or any combination thereof.
15. A dosage form according to any of claims 13-14, wherein the allergen is grass pollen.
16. A dosage form according to any of claims 13-14, wherein the allergen is dust mite.
17. A dosage form according to any of claims 1-14 comprising at least two different allergens.
18. A dosage form according to any of claims 1-17, wherein the potency is from 150 - 1000000 SQ-u/dosage form.
19. A dosage form according to any of claims 1-18, wherein the variation of content of allergen of units within a blister pack is ~10%, preferably ~7%, most preferable ~5 % compared to the dose set.
20. A dosage form according to any of claims 1-19 wherein the dosage form is for sublingual administration.
21. A dosage form according to any of claims 1 to 20, wherein said solid dosage form disintegrates in less than about 90 seconds, preferably in less than 60 seconds, preferably in less than 30 seconds, more preferably in less than 20, even more preferably in less than 10 seconds in the oral cavity, even more preferably in less than 5 seconds, most preferably in less than about 2 seconds in the oral cavity.
22. A dosage form according to any of claims 1 to 21, wherein said dosage form is sufficiently strong to be removed form a blister pack without releasing residues to the surroundings.
23. A dosage form according to claim 22, wherein less than 500 SQ-U of allergen, more preferably less than 250 SQ-U of allergen, most preferably less than 150 SQ-U of allergen is released from each solid dosage during manual handling.
24. A dosage form according to any of claims 1-23 wherein the friability measured as the amount of allergen released is less than 500 SQ-U per solid dosage form, more preferably less than 250 SQ-U per solid dosage form, most preferably less than 150 SQ-U per solid dosage form in a suitable friability test.
25. A dosage form according to claim 24, wherein the friability is measured in an assay comprising the following steps:
a) placing single units of solid dosage form contained in sealed blisterpack unit in an equipment suitable for reproducible friability measurements, b) moving it for an appropriate time and at an appropriate velocity, c) removing the sealed solid dosage form unit, d) opening the sealed solid dosage form unit and emptying the unit in a container/ placing the fast dispersing dosage form unit in a container, e) removing the solid dosage form unit from the container leaving any loose residues in said container, f) performing an allergen specific assay on said residues and determining the allergen content in said residues, g) optionally calculating the percentage of allergen content in said residues in comparison to total allergen content of the solid dosage form unit.
26. A dosage form according to claim 1, wherein at least a part of the active substance is present in the form of microcapsules embedded in the matrix, the microcapsules comprising a first encapsulating agent and the active substance.
27. A dosage form according to claim 25, wherein the first encapsulating agent is poly(DL-lactide-co-glycolide).
28. A dosage form according to any of the proceeding claims, wherein the dosage form is in the form of a granular composition suitable for preparing a compressed tablet.
29. A blister pack containing a number of a solid dosage forms according to any one of claims 1 to 28.
30. A method of preventing or treating a disease comprising oromucosal administration of an effective amount of a dosage form according to any of claims 1 to 27.
31. A method for preventing or treating allergy or alleviating symptoms of allergy comprising oromucosal administration of an effective amount of an allergen vaccine dosage form according to any of claims 1 to 27.
32. Use of a pharmaceutically active substance for the manufacture of a fast dispersing non-compressed solid dosage form according to claim 1.
33. Use of an allergen for the manufacture of a fast dispersing non-compressed allergen vaccine solid dosage form according to claim 1.
34. A fast dispersing non-compressed solid dosage form according to claim 1 for oromucosal prevention or treatment of a disease.
35. A fast dispersing non-compressed allergen vaccine solid dosage form according to claim 1 for oromucosal prevention or treatment of allergy or alleviation of allergic symptoms.
36. Use of a pharmaceutically active substance for the manufacture of a fast dispersing or non-compressed solid dosage form according to claim 1 for oromucosal prevention or treatment of a disease.
37. Use of an allergen for the manufacture of a fast dispersing or non-compressed allergen vaccine solid dosage form according to claim 1 for oromucosal prevention or treatment of allergy or alleviation of allergic symptoms.
38. A method of producing a fast dispersing non-compressed solid dosage form according to claim 1, comprising the steps of:

preparing an aqueous dosing solution of the pharmaceutically active substance and maltodextrin and optionally one or more further matrix forming agents and suitable excipients, introducing the solution into depressions of a multilayer laminated blister sheet, and subjecting the loaded sheet to freezing and freeze-drying using standard conditions of shelf temperature and chamber pressure.
39. A method of obtaining a fast dispersing non-compressed allergen vaccine solid dosage form suitable for oromucosal administration comprising 1) producing a fast dispersing, non-compressed solid allergen vaccine dosage form 2) measuring the friability of said dosage form in an assay comprising the steps of a) placing a solid dosage form contained in a sealed blister pack unit in an equipment suitable for friability measurements b) moving it for an appropriate time and at an appropriate velocity c) removing the sealed solid dosage form unit d) opening the sealed solid dosage form unit and emptying the unit in a container/ placing the fast dispersing dosage form unit in a container e) removing the solid dosage form unit from the container leaving any loose residues in said container f) performing an immunochemical allergen specific assay on said residues detecting the amount of allergen content in said residues g) calculating the percentage of allergen content in said residues in comparison to total allergen content of the solid dosage form unit h) detecting whether the dosage form fulfills the requirements for low friability.
3) repeating 1) and 2) until the requirements for the dosage form is fulfilled.
40. A compressed tablet comprising the granular composition of claim 28.
41. An aqueous dosing solution for preparing a fast-dispersing solid composition suitable for oromucosal administration of a pharmaceutically active substance, the dosing solution comprising (a) a first matrix forming agent in the form of maltodextrin having a dextrose equivalent (DE) of between 1 and 20, and (b) microcapsules comprising a first encapsulating matrix forming agent and the active substance.
42. A method of preparing the dosage form according to claim 28 comprising the steps of:
preparing microcapsules comprising a first encapsulating matrix forming agent and a pharmaceutically active substance, preparing an aqueous dosing solution of the microcapsules and maltodextrin and optionally one or more further matrix forming agents and suitable excipients, spray-freeing the dosing solution to produce primary granules, and freeze-drying the primary granules to produce secondary granules.
CA2516291A 2003-02-28 2004-02-24 Dosage form having a saccharide matrix Expired - Fee Related CA2516291C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300318 2003-02-28
DKPA200300318 2003-02-28
US46538303P 2003-04-25 2003-04-25
US60/465,383 2003-04-25
PCT/DK2004/000119 WO2004075875A1 (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix

Publications (2)

Publication Number Publication Date
CA2516291A1 true CA2516291A1 (en) 2004-09-10
CA2516291C CA2516291C (en) 2012-02-14

Family

ID=32929063

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2516291A Expired - Fee Related CA2516291C (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix

Country Status (9)

Country Link
EP (1) EP1599185A1 (en)
JP (1) JP4688787B2 (en)
KR (1) KR101136573B1 (en)
AU (1) AU2004216559B2 (en)
CA (1) CA2516291C (en)
HK (1) HK1089083A1 (en)
MX (1) MXPA05009079A (en)
PL (1) PL210707B1 (en)
WO (1) WO2004075875A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
US10023335B2 (en) 2010-03-29 2018-07-17 Ferring B.V. Fast dissolving pharmaceutical composition
US10086078B2 (en) 2010-03-29 2018-10-02 Ferring B.V. Fast dissolving pharmaceutical composition

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US20090155351A1 (en) 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
MY150626A (en) 2009-10-30 2014-02-07 Ix Biopharma Ltd Fast dissolving solid dosage form
JP5800527B2 (en) * 2010-03-30 2015-10-28 日東電工株式会社 Stabilized pharmaceutical composition, stabilized pharmaceutical composition solution preparation, film-form preparation and method for producing film-form preparation
EA024566B1 (en) * 2010-11-04 2016-09-30 Норджин Бв Solid formulation for oral administration (embodiments), method of therapeutically or non-therapeutically preventing gastrointestinal disorders or of maintaining gastrointestinal health using the same (embodiments) and pack comprising the same
JP2012240978A (en) * 2011-05-20 2012-12-10 Nitto Denko Corp Pharmaceutical composition and gelatinous preparation
JP2012240975A (en) * 2011-05-20 2012-12-10 Nitto Denko Corp Pharmaceutical composition and jerry-form preparation
EP3998080A1 (en) * 2013-03-14 2022-05-18 Société des Produits Nestlé S.A. Manufacture of peanut formulations for oral desensitization
EP2952200A1 (en) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergen for prophylactic treatment of allergy
GB2545880A (en) 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
WO2019101832A1 (en) * 2017-11-27 2019-05-31 Dsm Ip Assets B.V. Freeze-dried multiparticulate solid dosage form
JP6592791B1 (en) * 2018-01-29 2019-10-23 株式会社リタファーマ Pharmaceutical preparation and method for producing the same
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
CN116891827B (en) * 2023-09-08 2024-01-30 山东康华生物医疗科技股份有限公司 NK cell activity activation system

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD107208A1 (en) 1973-06-04 1974-07-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
FR2609895B1 (en) 1987-01-28 1991-06-28 Bruttmann Georges NEW GALENIC FORMS OF ALLERGENS FOR PER- AND SUB-LINGUAL ADMINISTRATION
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US6337082B1 (en) 1991-10-25 2002-01-08 Biovail Tech Ltd Saccharide-based matrix
US5343762A (en) 1992-10-05 1994-09-06 Rosemount Inc. Vortex flowmeter
US5343672A (en) * 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CN1120310A (en) * 1993-03-11 1996-04-10 塞科雷泰克公司 Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
US20020197321A1 (en) * 1997-10-27 2002-12-26 Harry Seager Solid dispersing vaccine composition for oral delivery
EP1062341B1 (en) 1998-03-16 2008-09-17 ALK-Abelló A/S Mutant recombinant allergens
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
FR2790387B1 (en) 1999-03-01 2001-05-18 Prographarm Laboratoires ORODISPERSIBLE TABLET HAVING LOW FRIABILITY AND PROCESS FOR THE PREPARATION THEREOF
US20060073188A1 (en) * 1999-03-31 2006-04-06 Pierre Fabre Medicament Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same
FR2791569B1 (en) 1999-03-31 2003-05-09 Pf Medicament ISOTROPIC FAST DISSOLVING ISOTROPIC MICROPOROUS COMPOSITION OR STRUCTURE FOR PHARMACEUTICAL, VETERINARY, DIETETIC, FOOD OR COSMETIC USE AND PROCESS FOR OBTAINING THE SAME
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
HUP0202537A3 (en) * 1999-08-24 2004-05-28 Teva Pharma A vaccine composition and method of using the same
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE19951970A1 (en) * 1999-10-28 2001-05-03 Bionetworks Gmbh Medicines for tolerance induction
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
ES2317955T3 (en) 2000-11-16 2009-05-01 Alk-Abello A/S MUTANT ALLERGENS.
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
ITMI20010571A1 (en) * 2001-03-19 2002-09-19 Grisotech S A TRANS-MUCOSAL ABSORBABLE VACCINES
EP1504089A2 (en) 2002-05-16 2005-02-09 Alk Abell A/S Allergen mutants

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023335B2 (en) 2010-03-29 2018-07-17 Ferring B.V. Fast dissolving pharmaceutical composition
US10086078B2 (en) 2010-03-29 2018-10-02 Ferring B.V. Fast dissolving pharmaceutical composition
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition

Also Published As

Publication number Publication date
JP4688787B2 (en) 2011-05-25
MXPA05009079A (en) 2006-05-19
PL378543A1 (en) 2006-05-02
WO2004075875A8 (en) 2004-12-29
HK1089083A1 (en) 2006-11-24
KR20050105491A (en) 2005-11-04
KR101136573B1 (en) 2012-04-23
AU2004216559A1 (en) 2004-09-10
CA2516291C (en) 2012-02-14
AU2004216559B2 (en) 2010-05-27
WO2004075875A1 (en) 2004-09-10
EP1599185A1 (en) 2005-11-30
PL210707B1 (en) 2012-02-29
JP2006519187A (en) 2006-08-24

Similar Documents

Publication Publication Date Title
CA2516291A1 (en) Dosage form having a saccharide matrix
KR101281147B1 (en) An allergen dosage form
ES2266820T4 (en) Desmopressin in an orodispersible dosage form
AU2002237548B2 (en) Intraorally rapidly disintegrable tablet
KR100655627B1 (en) Tablets quickly disintegrating in the oral cavity
US8012505B2 (en) Dosage form having a saccharide matrix
EP1236466B1 (en) Solid self-adhesive compositions for topical treatment of oral mucosal disorders
RU2189227C2 (en) Quickly decomposing, pressed in forms materials and method of their preparing
JP2006513269A5 (en)
JP2006519187A5 (en)
US20120135076A1 (en) Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20090155351A1 (en) Solid Vaccine Formulation
PL187160B1 (en) Compaction-moulded mouldings dissoluble in mouth fluids and method of making them
CA2720455A1 (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
BRPI0616879A2 (en) solid vaccine formulation
US20210346295A1 (en) Flowpack for oral delivery of active ingredients
RU2005120017A (en) ALLERGEN MEDICINAL FORM
RU2432171C2 (en) Immunostimulating drug and method for preparing it
KR20040046575A (en) The formulation and preparation of the tablet, granule, powder for fast disintegration and dissolution
Solan INTERNATIONALE PHARMACEUTICA SCIENCIA

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170224